Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma

Simon B. Zeichner*, Daniel A. Goldstein, Christine Kohn, Christopher R. Flowers

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Over the past 20 years, with the incorporation of genetic sequencing and improved understanding regarding the mechanisms of cancer growth/metastasis, novel targets and their associated treatments have emerged in oncology and are now regularly incorporated into the clinical care of patients in the US. Novel, more tumor-specific, non-chemotherapy agents, including agents that are commonly used in the treatment of patients with gastric adenocarcinoma (GA) and gastrointestinal stromal tumor (GIST), fall under a broader treatment strategy, termed "precision medicine". While diagnostic testing and associated treatments in metastatic GA (mGA) are costly and may produce marginal benefit, those associated with GIST, despite being costly, produce significant improvements in patient outcomes. Despite the significant difference in impact, the agents associated with these cancers have similar acquisition costs.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalJournal of Gastrointestinal Oncology
Issue number3
StatePublished - 1 Jun 2017
Externally publishedYes


  • Cost
  • Cost-effectiveness
  • Gastric adenocarcinoma (GA)
  • Gastrointestinal stromal tumor (GIST)
  • Targeted agents


Dive into the research topics of 'Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma'. Together they form a unique fingerprint.

Cite this